BRAF and Miyoshi myopathy: In the international, multicenter, randomized, phase III BRIM-3 trial, 675 patients with previously untreated, MM with the BRAF V600E mutation were randomly assigned to either vemurafenib (960 mg twice a day) or dacarbazine (1,000 mg/m2 IV Q3W) in patients who had either metastatic disease or unresectable stage IIIC disease.